Webinar: A new approach for your post-transplant CMV patients by Cmore

Sessions in this webinar

20h00

Opening session

Welcome and introduction, Topline results SOLSTICE trial, LIVTENCITY® reimbursement criteria and Q&A
20h45

Breakout room 1: Haematopoetic stem cell transplantation

Prof. Dr. Johan Maertens, Haematologist Universitair Ziekenhuis Leuven
20h45

Breakout room 2: Lung transplantation

Prof. Dr. Nicolaus Kneidinger, Pneumologist LMU Klinikum München
20h45

Breakout room 3: Kidney transplantation

Prof. Dr. Dirk Kuypers, Nephrologist Universitair Ziekenhuis Leuven
21h05

Closing session

Panel discussion and closure

This webinar is intended for Health Care Professionals only, with the exclusion of nurses.

LIVTENCITY® Summary of Product Characteristics

LIVTENCITY® is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

C-APROM/BE/LIV/0018 – January 2024

A new approach for your post-transplant CMV patients

About This Summit

Meet The Presenters

From theory to practice ... Register now and participate!